晚期肾上腺皮质癌局部疗法的当前证据

IF 2 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM
Hormone and Metabolic Research Pub Date : 2024-01-01 Epub Date: 2024-01-03 DOI:10.1055/a-2209-6022
Otilia Kimpel, Ulrich Dischinger, Barbara Altieri, Carmina Teresa Fuss, Bülent Polat, Ralph Kickuth, Matthias Kroiss, Martin Fassnacht
{"title":"晚期肾上腺皮质癌局部疗法的当前证据","authors":"Otilia Kimpel, Ulrich Dischinger, Barbara Altieri, Carmina Teresa Fuss, Bülent Polat, Ralph Kickuth, Matthias Kroiss, Martin Fassnacht","doi":"10.1055/a-2209-6022","DOIUrl":null,"url":null,"abstract":"<p><p>International guidelines emphasise the role of local therapies (LT) for the treatment of advanced adrenocortical carcinoma (ACC). However, large studies are lacking in this field. Therefore, we performed a review of the literature to synthesise current evidence and develop clinical guidance. PubMed database was searched for systematic literature. We identified 119 potentially relevant articles, of which 21 could be included in our final analysis. All were retrospective and reported on 374 patients treated with LT for advanced ACC (12 studies on radiotherapy, 3 on transarterial chemoembolisation and radioembolisation, 4 on image-guided thermal ablation [radiofrequency, microwave ablation, and cryoablation, and two studies reporting treatment with several different LT]). Radiotherapy was frequently performed with palliative intention. However, in most patients, disease control and with higher dosage also partial responses could be achieved. Data for other LT were more limited, but also point towards local disease control in a significant percentage of patients. Very few studies tried to identify factors that are predictive on response. Patients with a disease-free interval after primary surgery of more than 9 months and lesions<5 cm might benefit most. Underreporting of toxicities may be prevalent, but LT appear to be relatively safe overall. Available evidence on LT for ACC is limited. LT appears to be safe and effective in cases with limited disease and should be considered depending on local expertise in a multidisciplinary team discussion.</p>","PeriodicalId":12999,"journal":{"name":"Hormone and Metabolic Research","volume":null,"pages":null},"PeriodicalIF":2.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10764152/pdf/","citationCount":"0","resultStr":"{\"title\":\"Current Evidence on Local Therapies in Advanced Adrenocortical Carcinoma.\",\"authors\":\"Otilia Kimpel, Ulrich Dischinger, Barbara Altieri, Carmina Teresa Fuss, Bülent Polat, Ralph Kickuth, Matthias Kroiss, Martin Fassnacht\",\"doi\":\"10.1055/a-2209-6022\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>International guidelines emphasise the role of local therapies (LT) for the treatment of advanced adrenocortical carcinoma (ACC). However, large studies are lacking in this field. Therefore, we performed a review of the literature to synthesise current evidence and develop clinical guidance. PubMed database was searched for systematic literature. We identified 119 potentially relevant articles, of which 21 could be included in our final analysis. All were retrospective and reported on 374 patients treated with LT for advanced ACC (12 studies on radiotherapy, 3 on transarterial chemoembolisation and radioembolisation, 4 on image-guided thermal ablation [radiofrequency, microwave ablation, and cryoablation, and two studies reporting treatment with several different LT]). Radiotherapy was frequently performed with palliative intention. However, in most patients, disease control and with higher dosage also partial responses could be achieved. Data for other LT were more limited, but also point towards local disease control in a significant percentage of patients. Very few studies tried to identify factors that are predictive on response. Patients with a disease-free interval after primary surgery of more than 9 months and lesions<5 cm might benefit most. Underreporting of toxicities may be prevalent, but LT appear to be relatively safe overall. Available evidence on LT for ACC is limited. LT appears to be safe and effective in cases with limited disease and should be considered depending on local expertise in a multidisciplinary team discussion.</p>\",\"PeriodicalId\":12999,\"journal\":{\"name\":\"Hormone and Metabolic Research\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10764152/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Hormone and Metabolic Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1055/a-2209-6022\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/3 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hormone and Metabolic Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2209-6022","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/3 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

国际指南强调了局部疗法(LT)在治疗晚期肾上腺皮质癌(ACC)中的作用。然而,该领域缺乏大型研究。因此,我们对文献进行了综述,以总结现有证据并制定临床指南。我们在 PubMed 数据库中检索了系统性文献。我们发现了 119 篇潜在的相关文章,其中 21 篇可纳入我们的最终分析。所有文章均为回顾性研究,报告了374名晚期ACC患者接受LT治疗的情况(12项研究涉及放疗,3项研究涉及经动脉化疗栓塞和放射栓塞,4项研究涉及图像引导下的热消融(射频、微波消融和低温消融,还有两项研究报告了几种不同的LT治疗方法)。放疗通常以姑息治疗为目的。然而,大多数患者的病情得到了控制,在使用较大剂量的情况下也可获得部分反应。其他LT疗法的数据较为有限,但也表明相当一部分患者的局部疾病得到了控制。很少有研究试图找出可预测反应的因素。初次手术后无病间隔时间超过 9 个月的患者和病变
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Current Evidence on Local Therapies in Advanced Adrenocortical Carcinoma.

International guidelines emphasise the role of local therapies (LT) for the treatment of advanced adrenocortical carcinoma (ACC). However, large studies are lacking in this field. Therefore, we performed a review of the literature to synthesise current evidence and develop clinical guidance. PubMed database was searched for systematic literature. We identified 119 potentially relevant articles, of which 21 could be included in our final analysis. All were retrospective and reported on 374 patients treated with LT for advanced ACC (12 studies on radiotherapy, 3 on transarterial chemoembolisation and radioembolisation, 4 on image-guided thermal ablation [radiofrequency, microwave ablation, and cryoablation, and two studies reporting treatment with several different LT]). Radiotherapy was frequently performed with palliative intention. However, in most patients, disease control and with higher dosage also partial responses could be achieved. Data for other LT were more limited, but also point towards local disease control in a significant percentage of patients. Very few studies tried to identify factors that are predictive on response. Patients with a disease-free interval after primary surgery of more than 9 months and lesions<5 cm might benefit most. Underreporting of toxicities may be prevalent, but LT appear to be relatively safe overall. Available evidence on LT for ACC is limited. LT appears to be safe and effective in cases with limited disease and should be considered depending on local expertise in a multidisciplinary team discussion.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Hormone and Metabolic Research
Hormone and Metabolic Research 医学-内分泌学与代谢
CiteScore
3.80
自引率
0.00%
发文量
125
审稿时长
3-8 weeks
期刊介绍: Covering the fields of endocrinology and metabolism from both, a clinical and basic science perspective, this well regarded journal publishes original articles, and short communications on cutting edge topics. Speedy publication time is given high priority, ensuring that endocrinologists worldwide get timely, fast-breaking information as it happens. Hormone and Metabolic Research presents reviews, original papers, and short communications, and includes a section on Innovative Methods. With a preference for experimental over observational studies, this journal disseminates new and reliable experimental data from across the field of endocrinology and metabolism to researchers, scientists and doctors world-wide.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信